Trials / Completed
CompletedNCT04730947
Dapagliflozin (DAPA) Effects in HFpEF
Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | 10 mg orally once a day |
| DRUG | Placebo | Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2022-11-17
- Completion
- 2022-11-17
- First posted
- 2021-01-29
- Last updated
- 2023-10-12
- Results posted
- 2023-10-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04730947. Inclusion in this directory is not an endorsement.